Pharmacogenomics · 2014 · 51 citations · 32 references
MedicineOncologyPharmacologyChemotherapyDna RepairPharmacogenomicsCancer GenomicsCancer PharmacogenomicsChemotherapy PharmacogenomicsMalignant NeoplasmsPharmacodynamics Of Anticancer AgentsBreast Cancer GenomicsDna Repair MechanismsGenetic Risk VariantsInfusion-related Adverse ReactionsInfusion-related ReactionsPersonalized Treatment SelectionTaxane ChemotherapyTaxane Therapy
AIM: In order to identify genetic variants associated with taxanes toxicity, a panel with 47 SNPs in 20 genes involved in taxane pathways was designed. PATIENTS & METHODS: Genomic DNA of 113 breast cancer patients was analyzed (70 taking docetaxel, 43 taking paclitaxel). RESULTS: Two SNPs associated with docetaxel toxicity were identified: CYP3A4*1B with infusion-related reactions; and ERCC1 Gln504Lys with mucositis (p≤0.01). Regarding paclitaxel toxicity: CYP2C8 HapC and CYP2C8 rs1934951 were associated with anemia; and ERCC1 Gln504Lys with neuropathy (p≤0.01). CONCLUSION: Genes involved in DNA repair mechanisms and reactive oxygen species levels influence taxane toxicity in cancer patients treated with chemotherapy schemes not containing platinum. These findings could lead to better treatment selection for breast cancer patients.
32
Repression of gene expression by oxidative stress
Yannick Morel, Robert Barouki · Biochemical Journal · 1999 · 502 citations · Full text
XPD polymorphisms: effects on DNA repair proficiency
Ruth M. Lunn, Kathy J. Helzlsouer, R. Parshad et al. · Carcinogenesis · 2000 · 433 citations · Full text